Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060151 · ClinicalTrials.gov registry record · Phase 1
GW786034 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00060151: Completed Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT00060151 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060151, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.
Interventions
- DRUG pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00060151 record still lists
NCT00060151 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pazopanib hydrochloride is the first listed.
NCT00060151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060151 about?
NCT00060151 is a clinical study titled "GW786034 in Treating Patients With Advanced Solid Tumors". RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.
What is the current status of trial NCT00060151?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00060151?
The interventions under investigation include: pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00060151?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia